Legend Biotech (LEGN) EBITDA Margin (2019 - 2026)

Legend Biotech (LEGN) has reported EBITDA Margin for 8 consecutive years, with 16.32% the latest figure, recorded in Q1 2026.

• Quarterly EBITDA Margin rose 1019.0% year-over-year to 16.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.64% (up 359.0% YoY) and the FY2025 annual result came in at 13.27%, up 3607.0% from the prior year.
• EBITDA Margin slipped to 16.32% in Q1 2026 per LEGN's latest filing, from 6.43% in the prior quarter.
• Over the last five years, EBITDA Margin for LEGN reached as high as 473.89% in Q3 2022 and fell as low as 1581.66% in Q2 2022.
• A 5-year average of 20.16% and a median of 99.96% in 2023 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin sank 73009 bps — and 2023, when it jumped 180558 bps.
• Year by year, EBITDA Margin stood at 405.7% in 2022, then slumped by 75 bps to 99.96% in 2023, then tumbled by 143 bps to 42.52% in 2024, then soared by 85 bps to 6.43% in 2025, then slumped by 154 bps to 16.32% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 16.32%, 6.43%, and 15.96% for Q1 2026, Q4 2025, and Q3 2025 respectively.